|
|
|||
|
| |||
|
| |||
|
| |||
|
|
|||
|
Brian L Pearlman, Atlanta Medical Center, Medical College of Georgia, Emory School of Medicine, 285 Boulevard NE Suite 140 Atlanta, Georgia 30312, United States Correspondence to: Brian L Pearlman, MD, FACP, Center For Hepatitis C, Atlanta Medical Center, Medical College of Georgia, Emory School of Medicine, 315 Boulevard NE Suite 200, Atlanta, Georgia 30312, United States. brianpearlman@hotmail.com Telephone: +1-404-265-4644 Fax: +1-404-265-1047 Received: February 28, 2008 Revised: April 30, 2008 Accepted: May 7, 2008 Published online: June 21, 2008
Abstract With pegylated interferon and ribavirin, more than half of all chronically-infected hepatitis C patients can achieve a sustained virologic response; however, patients with genotype 1 infections and those with other poor prognostic factors have relatively inferior treatment response rates. Since new therapies are still years away from approval, it is incumbent upon providers to maximize the therapeutic efficacy of today’s treatment. The later the virus is undetectable in serum during treatment, the less likely it will be eradicated. Patients with a delayed or slow virologic response to therapy (at least a 2-log10 decrease in baseline hepatitis C RNA yet detectable viremia at 12 wk of therapy and undetectable virus 12 wk subsequently) may, therefore, benefit from an extended therapy course beyond one of standard duration. Although higher rates of treatment discontinuation may plague this approach, 72 wk of treatment for genotype 1-infected slow-responders may improve response rates and diminish relapse rates relative to those of 48 wk. Based on data from both viral kinetic and clinical studies, therapy prolongation in slow responders may be a reasonable strategy to improve response rates in these treatment-refractory patients.
© 2008 The WJG Press. All rights reserved.
Key words: Hepatitis C virus genotype; Peginterferon alpha; Ribavirin; Slow-responder; Extension
Peer reviewers: Dr. George V Papatheodoridis, 2nd Academic Department of Internal Medicine, Hippokration General Hospital, 114 Vas. Sofias ave., Athens 1527, Greece; Akihito Tsubota, Assistant Professor, Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567, Japan
Pearlman BL. Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it. World J Gastroenterol 2008; 14(23): 3621-3627 Available from: URL: http://www.wjgnet.com/1007-9327/14/3621.asp DOI: http://dx.doi.org/10.3748/wjg.14.3621
INTRODUCTION One hundred and seventy million persons worldwide are infected with the hepatitis C virus (HCV)[1], and liver-related deaths from the virus are expected to nearly triple by the year 2020[2]. Three years prior to the virus’ identification in 1986, interferon alpha-2b was first utilized for the treatment of non-A, non-B hepatitis[3]. Although sustained virologic response (SVR) rates to interferon monotherapy for 6 mo were only about 8%, treatment extension to 12 mo nearly doubled response rates[4]. With the advent of the nucleoside analog ribavirin, used in combination with interferon, rates of SVR more than doubled again[5,6]. Whereas 48 wk of standard interferon with ribavirin achieved sustained response rates as high as 43%[6], 48 wk of the newer pegylated interferons plus ribavirin improved rates of SVR to 54%-56% as shown in two multinational, randomized controlled trials[7,8]. Nevertheless, SVR rates are inferior for patients with genotype 1 infection[7-9] despite a 48 wk recommended treatment course of peginterferon with weight-based ribavirin[10,11]. Although preliminary evidence indicates that small molecule inhibitors in combination with peginterferon and ribavirin may improve response rates even further for genotype 1-infected patients with merely 24 wk of therapy[12,13], the combination of peginterferon and ribavirin alone is likely to remain the recommended treatment regimen for chronic HCV for the next 3-5 years[14]. Thus, it is incumbent upon clinicians to maximize their patients’ chance of treatment success with existing therapy. Methods utilized to improve the treatment response in genotype 1-infected patients include the bolstering of patient adherence through aggressive side effect management and increasing the dose of therapy through induction dosing of interferon or through higher doses of either interferon or ribavirin. Another strategy is to lengthen duration of treatment in those that are slow-responders to standard doses of peginterferon and ribavirin. The purpose of this survey is to review the justification for therapy prolongation in appropriate patients using viral kinetic data and to summarize the clinical trials supporting this approach.
VIRAL KINETICS DURING TREATMENT
An initial decrement in HCV RNA level, referred to as
phase 1, occurs hours after the administration of interferon; it
represents the blocking of viral replication. A subsequent, slower
decrease in viremia (phase 2) represents the clearance of HCV-infected
hepatocytes and typically occurs days to months after interferon
therapy is initiated. The phase 2 decline in virus is the better
predictor of ultimate HCV clearance[15,16]. Phase 2 HCV-infected patients who achieve undetectable viremia as early as 4 wk into standard therapy have excellent sustained response rates; these rapid virologic responders achieve SVR about 90% of the time[19]. In fact, support exists for truncating therapy duration for genotype 1-infected rapid responders with low baseline HCV viral loads[20]. Conversely, patients who show undetectable virus for the first time 24 wk into therapy have less than one-third chance of ultimately achieving SVR[8]. Therefore, the earlier the HCV is undetectable in serum during treatment, the greater the likelihood of a successful treatment response (Figure 1).
Similarly, longer durations of viral suppression on
treatment may improve virologic response rates. Investigators have
sought to determine if the standard 48 wk treatment duration of
patients with genotype 1 infection is adequate. Using data from the
peginterferon alpha-2b and ribavirin phase
Ⅲ
trial[7], Drusano and Preston developed a prediction
model based on the duration of viral suppression on therapy[21].
The model was built on the basis of eleven covariables including
demographics and virologic characteristics from 771 HCV-infected
patients. Among the variables, the durations of viral clearance had
the strongest bearing on the likelihood of a SVR. When the model was
applied to a validation group of 229 patients, it predicted SVR with
a positive predictive value of 97% and a negative predictive value
of 91%. To achieve an 80% chance of SVR in genotype 1-infected
patients, an undetectable HCV RNA was required for at least A failure to achieve an early virologic response (EVR), defined by an undetectable HCV RNA level or at least a 2-log10 decrement in RNA from baseline at 12 wk of therapy, has excellent negative predictive value for treatment success[22,23]. An analysis of the peginterferon with ribavirin registration trials[7,8] suggests that patients who do not achieve a 12 wk EVR have a 3% or lower chance of ultimately achieving SVR[23]. Nonetheless, there is a large disparity in treatment response between patients who, at 12 wk, have at least a 2-log10 decrease in baseline HCV RNA yet still have detectable virus (partial EVR) compared to those who achieve undetectable viremia (complete EVR). In the registration trial for peginterferon alpha-2b with ribavirin, patients in the latter group achieved SVR about four times more frequently than those in the former[23]. These former patients are said to be slow or late responders to therapy. Patients have also been characterized as slow responders to therapy if they have detectable virus at 4 wk; either definition necessitates undetectable virus at 24 wk of treatment, since detectable viremia at this time point virtually guarantees treatment failure. In genotype 1 infection with the standard therapy duration of 48 wk, slow responders have higher relapse rates compared to those that clear virus earlier in treatment[19]. High rates of relapse in slow responding patients may indicate that therapy was of insufficient duration; therefore, it has been hypothesized that extending therapy in these patients may improve rates of SVR (Figure 2).
EXTENDED DURATION THERAPY WITH STANDARD INTERFERON Several years before the term slow-responder was popularized, investigators attempted to improve response rates by extending therapy duration utiliz-ing older medications. Using standard interferon monotherapy, authors have demonstrated improved biochemical, histologic and virologic responses with treatment ranging from 60 to 76 wk compared to treatments of shorter durations[24,25]. In one of these studies[24], the investigators noted a reduced tendency for patients to relapse after treatment cessation when therapy was extended to 60 wk relative to previously published studies with shorter durations. The first randomized, controlled trial to show that prolongation of interferon-based therapy combined with ribavirin for 18 mo reduced rates of relapse was performed in the Netherlands and Belgium[26]. Three hundred treatment-naive chronic HCV patients were randomized to 6 or 18 mo of standard-interferon (3 million units thrice weekly) plus ribavirin (1000-1200 mg daily) or to 18 mo of the same dose of standard interferon monotherapy plus placebo. The majority of patients were genotype 1-infected with high viral loads. Although end-of-treatment responses were similar in the two combination therapy arms (55% and 41% in 6 and 18 mo arms, respectively), relapse rates were significantly lower in the 18 mo combination arm (13%) compared to those in the 6 mo treatment arm (38%, P = 0.006). It should be noted that the rate of relapse in the group treated with 18 mo of monotherapy was still high at 38%; these results demonstrate that extending the duration of interferon alone is inadequate to decrease relapse rates and attests to ribavirin’s effect on relapse diminution. In an intention-to-treat analysis, SVR rates were 16% for 18 mo monotherapy, 34% for 6 mo combination therapy and 43% for 18 mo of combination therapy (P < 0.05). Although 25% of patients withdrew from both 18 mo treatment arms prematurely, this withdrawal rate is similar to those from standard interferon plus ribavirin treatment trials of 48 wk duration (21%-27%)[5,6]. Prolongation of combination therapy had no significant effect on rates of relapse or SVR in genotype 2- or 3- infected patients; nevertheless, extension of treatment from 6 to 18 mo had an independent effect on relapse and SVR rates in patients infected with genotype 1 virus (SVR: OR 4; CI: 2-10, P = 0.004). Slow responders, those with detectable viremia at 12 wk, enjoyed a decline in relapse rate from 70% to 30% when treatment was prolonged from 24 to 72 wk. The study’s major limitation was the absence of a 12 mo treatment arm.
EXTENDED DURATION THERAPY WITH PEGYLATED INTERFERON Investigators from Spain and Israel were the first to report successful treatment extension to 72 wk for slow responders to peginterferon and ribavirin[27]. Slow responders were defined as those patients with at least a 2 log10 decline in HCV RNA from baseline, yet detectable viremia at 12 wk after receipt of 1.0 mcg of peginterferon alpha-2b weekly and 800 mg ribavirin daily. Although only 8 patients were treated in this fashion, 7 of the 8 (88%) achieved an SVR, which is a profound improvement relative to a SVR of 21% in slow responders treated for 48 wk in the phase Ⅲ trial of peginterferon alpha-2b and ribavirin[23]. The suboptimal dosing of ribavirin and the paucity of patients studied are the limitations of this analysis.
Furthermore, results from a large, prospective,
multicenter trial from Germany support the extension of therapy
duration in slow responders to peginterferon and ribavirin[28].
459 treatment-naïve genotype 1-infected patients were randomized to
48 wk vs 72 wk of peginterferon alpha-2a, 180 mcg weekly and
ribavirin, 800 mg daily. 22% of patients were slow virologic
responders to therapy, defined by virus detectability at 12 wk of
treatment, but with viral undetectability at 24 wk. Slow responders
in the 72 wk group had lower relapse rates than did slow responders
treated for 48 wk Another randomized, multicenter clinical trial from Spain, the TeraViC-4 study, prospectively evaluated the effects of extended therapy duration with peginterferon alpha-2a (180 mcg weekly) and ribavirin (800 mg daily)[29]. Treatment-naïve patients with detectable HCV RNA levels at week 4 (n = 326) were randomized to a therapy duration of 48 wk (n = 165, 149 of whom were genotype 1-infected) or to 72 wk (n = 161, 142 of whom were genotype 1-infected). Thus, in this case, a slow responder was defined by absence of a rapid virologic response, and only slow responders were randomized to extended therapy. In TeraViC-4, the 12 wk virologic responses were not reported. Although end-of-treatment responses for patients with genotype 1 infections were statistically similar in both extended and standard treatment arms (62% vs 58%, respectively; P = 0.53), SVR rates were superior in the extended treatment arm (44% vs 28%, respectively; P = 0.003), by virtue of a diminution of relapse rate (17% vs 53%, respectively; P = 0.002). The incidence of adverse events and dose reductions were similar in both groups; yet, treatment discontinuation was more frequent in the extended therapy arm compared to the standard duration arm (36% vs 18%, respectively; P = 0.0004). In fact, one of the study’s limitations was this inordinate number of premature terminations in those randomized to prolonged therapy, largely because of patient preference. Other limitations were the lack of central testing for viral load measurements and the inclusion of patients with other genotypes besides one. Like that of the German study, the primary weakness of this trial may have been the suboptimal dose of ribavirin utilized (800 mg for genotype 1 virus). In another prospective study from the United States, we randomized genotype 1-infected slow-responders to 48 or 72 wk of peginterferon alpha-2b (1.5 mcg/kg weekly) and weight-based ribavirin (800 to 1400 mg daily)[30]. In our trial, slow response was defined by achieving at least a 2 log10 decrement in HCV RNA from baseline, yet having detectable viremia at 12 wk but undetectable virus at 24 wk (PCR, lower limit of detection 10 IU/mL). One hundred twelve of our treatment-naïve patients were deemed slow-responders who represented about 30% of our patients. This percentage was felt to be high secondary to difficult-to-treat baseline characteristics: 26% had bridging fibrosis or cirrhosis on pre-treatment liver biopsy; 48% were African American; 34% were obese defined by greater than or equal to 30 kg/m2; 78% had high baseline viral load (more than 800 000 IU/mL) and 18% had impaired fasting glucose, pre-treatment. Similar to the aforementioned European trials, we did not observe a higher number of adverse events or therapy reductions in the extended treatment arm relative to the control arm. However, unlike in the other studies, we did not see a greater treatment cessation rate in the prolonged therapy arm; in fact, none of the therapy terminations occurred between weeks 48 and 72. Growth factors were prohibited, yet peginterferon dose reductions for neutropenia were made only if counts were less than 500/mm3. Similar to those of the slow-responders in Spain, our randomized patients saw equivalent end-of-treatment response rates in the 72 wk arm vs the 48 wk arm (48% vs 45%, respectively; P = 0.75), yet enjoyed improved relapse rates with therapy prolongation (20% vs 59%, respectively; P = 0.004). Overall, rates of SVR in slow-responders were superior with treatment extension (38%) compared to those of standard duration therapy (18%, P = 0.03). The primary limitation of our analysis is it was conducted in a single medical center. African Americans, a group with inferior responses to interferon-based therapy[31-33], may likewise benefit from a treatment extension strategy if slowly responsive to treatment. When compared to non-Hispanic whites receiving combination therapy, African Americans showed smaller phase 1 and phase 2 declines in viral load[34]; thus, it was unclear if African Americans’ viral kinetics on therapy would be analogous to those of white “late” responders. Nearly half of our slow responders were self-identified as African American (n = 48) and were randomized to 48 and 72 wk treatment arms in our Atlanta study described above[30]. Although overall, African American slow responders had expected inferior SVR rates to those of whites (17% and 39%, respectively), the former group still benefited from treatment extension because of reduced relapse rates. End-of-treatment response rates were 24% vs 26% for 48 and 72 wk of treatment, respectively (P > 0.05), and SVR rates were 12% vs 21%, respectively (P = 0.02). Results should be interpreted with caution, however, because this ethnic group’s response rates were derived from subgroup analysis. Preliminary results are available from a multicenter trial in Europe that also utilized extended therapy for slow-responders to peginterferon alpha-2a (180 mcg weekly) with weight-based ribavirin (1000-1200 mg daily)[35,36]. Of the 373 patients treated, 11% were slow-responders to therapy, defined by having detectable virus at 12 wk (> 50 IU/mL), yet still at least 2 log10 below baseline, and thus randomized to complete standard duration therapy of 48 wk or extended treatment to 72 wk. None of these slow-responders had achieved undetectable virus at 4 wk. Over 90% of patients had genotype 1 infections, and the remainder was infected with genotype 4 virus. As in the previously described studies, extended therapy compared to that of standard duration improved SVR rates in slow-responders (69% vs 52%, respectively; P value not available) by virtue of a decrease in relapse rates (18% vs 32%, respectively; P value not available). Although treatment discontinuation data are not available for slow-responders specifically, patients who received extended duration therapy had a greater number of treatment discontinuations (17%) compared to those on standard duration therapy (4%). Limitations of this study are the small numbers of slow-responders analyzed (41 patients) and the mixture of genotype 1- and 4- infected patients. Finally, a recently published, randomized, multicenter study from Italy assessed the utility of variable therapy duration, including a treatment extension strategy, based on the time to a patient’s first undetectable HCV RNA[37]. 696 genotype 1-infected treatment-naive patients were randomized to a standard duration or a variable duration therapy arm in a 2:1 ratio. Patients were treated with either peginterferon alpha-2a (180 mcg weekly) or peginterferon alpha-2b (1.5 mcg/kg weekly), both with weight-based ribavirin (1000-1200 mg daily). Irrespective of first time to viral undetectability in serum (< 50 IU/mL), 237 patients in the standard therapy arm received treatment for 48 wk, unless patients did not achieve EVR at week 12 or had detectable virus at week 24, at which time therapy was discontinued. However, in the variable duration arm, patients were treated for 24, 48 or 72 wk if serum HCV RNA were negative at 4, 8, or 12 wk, respectively. Patients were likewise treated for 72 wk in the variable duration arm if they had at least a 2 log10 decline in serum RNA from baseline yet detectable viremia at 12 wk of therapy (slow-responders). Overall, based on the rates of SVR, the standard and variable duration treatment arms were statistically equivalent. Nonetheless, the study proved prospectively that the longer the virus is undetectable on therapy, the better the chance of achieving a SVR, regardless if a patient had received treatment of a standard or variable duration. In the standard duration arm, 87%, 70% and 38% of patients first attaining undetectable viremia at 4, 8 or 12 wk, respectively, achieved SVR; in the variable duration group, corresponding SVR rates were 77%, 72% and 64%.
More pertinent to this discussion is the fact that
the study’s slow-responders in the standard treatment duration arm (n
= 21) did not achieve SVR in a single case (0%), and those
slow-responders treated for 72 wk The most important limitations of this last study are the large number of patients in the variable treatment duration arm who discontinued therapy because of poor compliance (49% of all treatment discontinuations), and the relative paucity of patients on which subgroup analysis was performed. For example, only 21 slow-responders were treated for 48 wk. The Study to Assess Treatment with Pegylated Interferon Alpha-2b and Ribavirin in Treatment-Naive Patients with Chronic hepatitis C and slow virologic response (SUCCESS) is a multinational study in 133 centers across Europe, Canada and Israel designed to compare response rates of slow-responders to either 48 or 72 wk of therapy[38]. Slow-response is again defined by patients with genotype 1 infection who had at least a 2 log10 reduction, albeit detectable, HCV RNA levels at 12 wk compared to baseline and undetectable virus at week 24. As of late 2006, 126 patients were deemed slow-responders and were randomized into standard and extended therapy duration arms (Table 1). Final results should be available sometime later in 2008 or in early 2009.
CONCLUSION Treatment extension has been attempted with varying degrees of success using alternative interferons[39,40], in those with relapse[40] or non-response to peginterferon-based therapies[41] and in those who are HCV-HIV coinfected[42,43]. Details of these analyses are beyond the scope of this review. Certainly, not every treatment-naive patient with genotype-1 infection benefits from therapy prolongation. However, a subgroup with a delayed or slow response to therapy (approximately 15% of patients) may enjoy improved rates of SVR with treatment extension to 72 wk, largely because of a relapse diminution. Data on therapy prolongation in slow-responders are summarized in Table 1. Compared to patients receiving therapy of standard duration, those in extended treatment groups have experienced higher discontinuation rates in most, but not all, studies to date; however, the numbers of adverse events and dose reductions appear to be equivalent. Clearly, if treatment prolongation is utilized, adherence to therapy is paramount. Finally, the use of 72 wk for slow virologic responders to peginterferon and ribavirin may be cost-effective compared to 48 wk, or standard duration therapy[44]. Thus, therapy extension in slow-responders seems to be a reasonable strategy to ameliorate response rates in a group with notoriously poor treatment results.
REFERENCES 1 Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47 PubMed 2 Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562 PubMed 3 Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-1578 PubMed 4 Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26: 83S-88S PubMed 5 McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492 PubMed 6 Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432 PubMed 7 Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965 PubMed 8 Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 PubMed 9 Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 PubMed 10 Dienstag JL, McHutchison JG. American Gastro-enterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-230 PubMed 11 Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171 PubMed 12 Jacobson IM, Everson GT, Gordon SC, Kauffman R, McNair L, Muir A, McHutchison JG. Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naïve subjects with hepatitis C. Hepatology 2007; 46: 315A-316A 13 Hezode C, Ferenci P, Dusheiko GM, Pol S, Goeser T, Bronowicki JP, Gharakhanian S, Devonish D, Kauffman R, Alam J, Pawlotsky JM, Zeuzem S. PROVE 2: phase II study of VX-950 (Telaprevir) in combination with peginterferon alfa-2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. Hepatology 2007; 46: 268A-269A 14 Modi AA, Hoofnagle JH. New therapies for hepatitis C. Hepatology 2007; 46: 615-617 PubMed 15 Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231 PubMed 16 Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107 PubMed 17 Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35 PubMed 18 Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 1438-1447 PubMed 19 Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Chaneac M, Reddy KR. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433 PubMed 20 Davis GL. Tailoring antiviral therapy in hepatitis C. Hepatology 2006; 43: 909-911 PubMed 21 Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964-970 PubMed 22 Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-1156 PubMed 23 Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652 PubMed 24 Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, Yun ZB, Weiland O. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994; 19: 280-285 PubMed 25 Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332: 1457-1462 PubMed 26 Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, Lefebvre V, Van Hattum J, Henrion J, Delwaide J, Hansen BE, Schalm SW, For The Benelux Study Group On Treatment Of Chronic Hepatitis C. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004; 40: 689-695 PubMed 27 Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 2003; 37: 1226-1227 28 Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097 PubMed 29 Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, Crespo J, Andrade R, Martinez- Bauer E, Perez R, Testillano M, Planas R, Sola R, Garcia-Bengoechea M, Garcia-Samaniego J, Munoz-Sanchez M, Moreno-Otero R. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-460 PubMed 30 Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46: 1688-1694 PubMed 31 Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271 PubMed 32 Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-1708 PubMed 33 Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477 PubMed 34 Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV- infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 1343-1350 PubMed 35 Ferenci P, Laferi H, Scherzer T, Maieron A, Gschwantler M, Brunner H, Hubmann R, Bischof M, Staufer K, Datz C, Steindl-Munda P, Kessler H. Customizing treatment with peginterferon alfa-2a plus ribavirin in patients with HCV genotype 1 or 4 infection. Interim analysis of a prospective, randomized trial. Hepatology 2006; 44: 336A 36 Sanchez-Tapias JM, Ferenci P, Diago M, Romero-Gomez M, Zeuzem S, Berg T. Which genotype 1 patients may benefit from extended treatment duration with peginterferon alfa-2a plus ribavirin? Proceedings of the 17th Asian Pacific Association Study of Liver Disease conference, Kyoto, Japan. Hep Intl 2007; 1: 242 37 Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47: 43-50 PubMed 38 Buti M, Lurie Y, Blokhina N, Teuber G, Holota W, Sumskiene J, Vozianova Z, Wong F, Winkler R, Esteban R. Pegylated interferon alfa-2b plus ribavirin in patients with genotype 1 chronic hepatitis C with a slow virologic response: an early enrollers analysis of the SUCCESS study. Hepatology 2006; 44: 342A 39 Kaiser S, Holger H, Bissinger L, Bettina L, Sauter B, Gregor M. Extended treatment of 72 versus 48 weeks for chronic hepatitis C patients with genotype 1 and high viral load using daily consensus interferon and ribavirin. Hepatology 2006; 44: 608A 40 Kaiser S, Lutze B, Sauter B, Bissinger L, Werner C, Hass H, Gregor M. Retreatment of HCV genotype 1 relapse patients to peginterferon/ribavirin therapy with an extended treatment regimen of 72 weeks of consensus interferon/ribavirin versus peginterferon alpha/ribavirin. Hepatology 2007; 46: 819A 41 Jensen DM, Frelich B, Andreone P, DiBisceglie A, Brandao-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Hooper G, Popescu M, Marcellin P. Pegylated interferon alfa-2a plus ribavirin in prior non-responders to pegylated interferon alfa-2b/ribavirin: final efficacy and safety outcomes of the REPEAT study. Hepatology 2007; 46: 291A-292A 42 Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaro J, Roget M, Garcia I, Pedrol E, Tor J, Ballesteros AL, Salas A, Sirera G, Videla S, Clotet B, Tural C. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir Ther 2006; 11: 473-482 PubMed 43 Nunez M, Miralles C, Berdun MA, Losada E, Aguirre-bengoa K, Ocampo A, Arazo P, Cervantes M, de Los Santos I, San Joaquin I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, Garcia-Samaniego J, Soriano V. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972-982 PubMed 44 Nakamura J, Toyabe SI, Aoyagi Y, Akazawa K. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat 2008; 15: 293-299 PubMed
S- Editor Li DL L- Editor Li M E- Editor Lin YP
| |||
|
|
